Navigation Links
MDS Inc. Completes Divestiture of MDS Pharma Services Phase II-IV Operations
Date:7/1/2009

    MDS Pharma Services to Focus on the Delivery of Early Stage Services -
    Discovery Through Phase IIa

TORONTO, July 1 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE: MDZ), a leading provider of products and services to the global life sciences markets, today announced that it has completed the divestiture of its Phase II-IV operations to INC Research,(R) Inc.

Under the terms of the agreement, INC Research, a leading global provider of contract research organization services headquartered in Raleigh, North Carolina, has acquired MDS Pharma Services Phase II-IV operations, which includes approximately 800 employees who conduct large, multi-site clinical trials in more than 25 countries.

"The completion of this transaction supports our efforts to advance MDS Pharma Services' top-three leadership position in the delivery of Early Stage services," said Stephen P. DeFalco, President and Chief Executive Officer of MDS Inc.

MDS expects to provide additional detail with respect to the divestiture of its Phase II-IV operations when the Company reports financial results for its fiscal third quarter (three months ending July 31, 2009).

The Company's decision to sell its MDS Pharma Services Late Stage operations, which are comprised of Phase II-IV operations and Central Labs, are a result of MDS's ongoing strategic review process.

A suitable buyer is being sought for Central Labs, which conducts analysis of clinical-trial samples to monitor safety and to test for physiological impact. Central Labs has more than 600 employees at six sites in Europe, North America and Asia.

MDS Pharma Services' New Strategic Focus

Additional background materials pertaining to the new strategic focus for MDS Pharma Services can be found on MDS Inc.'s Website at www.mdsinc.com/for_media/electronic_media_kit.asp

About INC Research,(R) Inc.

INC Research is a therapeutically focused contract research organization with a high performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in therapeutic areas of specialty, and in innovative pediatric and women's health trials. The company's The Trusted Process(R) methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, North Carolina. For more information please visit www.incresearch.com.

About MDS

MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides market-leading products and services that our customers need for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 4,200 highly skilled people in 13 countries. Find out more at www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.


'/>"/>
SOURCE MDS Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Lumenis Completes $15 Million Equity Financing From New and Existing Investors
2. CEL-SCI Completes $5.85 Million Registered Direct Offering
3. Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial
4. BioMed Realty Trust Completes $350 Million Financing for Center for Life Science Boston
5. Acclarent, Inc. Completes Office-Based Study Using Balloon Sinuplasty(TM) Technology
6. Cell Therapeutics Completes Pixantrone NDA Submission and Requests Priority Review
7. NeuroTherm Completes Acquisition of the Micron Epidural Catheter
8. Homefront Diabetic Services Completes Accreditation with ACHC
9. STAAR Surgical Completes Common Stock Offering
10. SETO Holdings, Inc. Completes Agreement to Acquire Advanced Hearing Centers, Inc. and Has Disposed of All Existing Business; New Management has been installed
11. Inspire Medical Systems Completes $17 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Seattle, WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens ... technologies for low-resource settings. The partnership will recruit top students from U.S. ...
(Date:2/12/2016)... ... 12, 2016 , ... Each year, the American Physical Therapy Association (APTA) offers ... the Anaheim Convention Center. Almost 10,000 physical therapists across the country are expected to ... more about their chosen field and network with their colleagues. As in years ...
(Date:2/12/2016)... Appleton, Wis. (PRWEB) , ... February 12, 2016 ... ... its second Lean Leadership Series at Zuckerberg San Francisco General Hospital on April ... to practice new behaviors and create new habits. The workshops cover a broad ...
(Date:2/12/2016)... Washington, NC (PRWEB) , ... February 12, 2016 , ... ... the surrounding areas, is initiating a charity drive that will raise funds earmarked to ... at John C. Tayloe Elementary School. , “My school is in a low-income area ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... of the Pittsburgh metro area, celebrates the beginning of the latest charity campaign ... develop social skills through art. Donations to this worthy cause are currently being ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ ... Company will ring the Nasdaq Closing Bell at the ... at 4:00 p.m. ET on Tuesday, February ... Adrian Adams , will perform the honorary ... 4:00 p.m. ET.  A live webcast will be available ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis Pharmaceuticals, ... a $47.1 million Series D preferred stock ... Management, Hillhouse Capital Group and venBio Global ... Investments, AJU IB Investment, and Epidarex Capital. The ... to further advance clinical trials in the ...
(Date:2/11/2016)... 2016 - Cardiac Marker ... Medicine and Cancer Therapy. - European Point of ... Markets. - Key Diagnostic Testing Markets. - ... in Genetic Testing. - Molecular Diagnostics in Infectious ... Over-the-Counter Diagnostic Products World Markets. - Point of ...
Breaking Medicine Technology: